Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of RT001 for lateral canthal lines
NCT01124565Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- May 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RT001 in lateral canthal rhytides, sponsored by Revance Therapeutics. Started May 2010; status: completed.
02
Drugs
RT001
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT01124565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01124565.